𝔖 Bobbio Scriptorium
✦   LIBER   ✦

3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)

✍ Scribed by E. van Cutsem; G. Bodoky; J. Kyung Roh; G. Folprecht; Y.S. Park; J.L. van Laethem; J.L. Raoul; F. Ciardiello; P. Lebrun; P. Rougier

Book ID
118625771
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
58 KB
Volume
5
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa πŸ“‚ Article πŸ“… 2014 πŸ› Lancet Publishing Group 🌐 English βš– 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow